{"id":"W2948352962","doi":"10.1182/bloodadvances.2018030387","title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update","year":2019,"lang":"en","type":"review","venue":"Blood Advances","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"Cilag; National Cancer Institute; Italfarmaco; Ipsen; Servier; Kyowa Hakko Kirin; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Daiichi Sankyo Europe; Sanofi; Biogen; Celgene; American Society of Clinical Oncology; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Biosimilar; Anemia; Randomized controlled trial; Internal medicine; Cancer; Intensive care medicine; Epoetin alfa; Guideline; Cochrane Library; Oncology; Myelodysplastic syndromes; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01295313,0.001566643,0.003797416,0.005337344,0.0008804926,0.002056558,0.005414953,0.006160834,0.003010751],"category_scores_gemma":[0.03586879,0.0007107645,0.005165172,0.004855781,0.0009843764,0.002427599,0.002157097,0.00646472,0.002524921],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003419613,"about_ca_system_score_gemma":0.01315521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01263341,"about_ca_topic_score_gemma":0.0213183,"domain_scores_codex":[0.9907047,0.003059441,0.003196437,0.0002953489,0.00248495,0.0002590526],"domain_scores_gemma":[0.9665559,0.01140273,0.005385214,0.0005493218,0.01495409,0.001152651],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001947735,0.0002035572,0.00179626,0.03651968,0.0007686271,0.0003073334,0.0002990475,0.001038219,0.000555852,0.002147252,0.4933969,0.4627725],"study_design_scores_gemma":[0.0006562356,0.0002081766,0.005671579,0.1557551,0.002929798,0.001349927,0.0003428453,0.001383339,0.0008746458,0.006411229,0.8242944,0.000122679],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002114484,0.7596257,0.01100986,0.1946358,0.008917366,0.002520517,0.004354951,0.0005324917,0.0162888],"genre_scores_gemma":[0.01251825,0.8000364,0.09085761,0.07254035,0.005895419,0.004307845,0.00735726,0.0002102998,0.006276587],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01295313,"threshold_uncertainty_score":0.06850356,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05770829144142951,"score_gpt":0.4484844334443418,"score_spread":0.3907761420029123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}